title: The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
abstract: OBJECTIVE
  To investigate the predictors of response to neoadjuvant chemotherapy (NACT) in advanced stage epithelial ovarian cancer (EOC).
  
  
  METHODS
  Thirty-five patients with nonoptimally cytoreductable at stage III-IV EOC who were treated with NACT and interval cytoreductive surgery in our center between January 2002 and February 2009 were enrolled into this retrospective pilot study. Response to NACT was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST).
  
  
  RESULTS
  All patients received three courses platinum-based chemotherapy [24 (69%) received pactitaxel plus carboplatin and 11 (31%) received paclitaxel plus cisplatin]. There were 12 (34%) partial response to and 23 (66%) stable disease after NACT. Optimal cytoreduction was subsequently achieved in 32 of 35 patients (91%). Among age, hystology, ovarian size, CA-125 level, severity of pleural effusion, extensive omental disease, diaphragmatic implants, liver parenchyma metastasis, used chemotherapy regimen; only extensive omental disease was found to be predictive (P = 0.004).
  
  
  CONCLUSIONS
  Ovarian cancer patients with extensive omental disease were possibly better treated with primary cytoreductive surgery, since they were more likely to have less responsive to NACT. This finding can be used to identify patients who will get poor response to NACT and to design future tailored randomized clinical trials.
authors.affiliation: Department of Gynecologic Oncology, Aegean Obstetrics and Gynecology Education and Research Hospital, Izmir, Turkey.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yildirim
authors.forename: Ibrahim Egemen
authors.initials: IE
authors.lastname: Ertas
authors.forename: Askin
authors.initials: A
authors.lastname: Dogan
authors.forename: Ozge Elmastas
authors.initials: OE
authors.lastname: Gultekin
authors.forename: Emre
authors.initials: E
authors.lastname: Gultekin
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009852:Omentum / Q000187:drug effects / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010865:Pilot Projects; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin